Current Oncology Reports

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies
Current Oncology Reports - Tập 25 - Trang 569-587 - 2023
Santhosshi Narayanan, Aline Rozman de Mores, Lorenzo Cohen, Mohammed Moustapha Anwar, Felippe Lazar, Rachel Hicklen, Gabriel Lopez, Peiying Yang, Eduardo Bruera
Patients seek clinical guidance on mushroom supplements that can be given alongside conventional treatments, but most research on such fungi has been preclinical. The current systematic review focused on clinical studies of mushrooms in cancer care conducted in the past 10 years. We searched Medline (Ovid), Embase (Ovid), Scopus (Wiley), and Cochrane Library to identify all mushroom studies condu...... hiện toàn bộ
Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors
Current Oncology Reports - Tập 11 - Trang 322-328 - 2009
Brigitte C. Widemann
Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas that rarely occur in the general population but have a lifetime incidence of 8% to 13% in those with neurofibromatosis type 1 (NF1). Complete surgical resection is the standard treatment for MPNSTs. Unresectable MPNSTs carry a poor prognosis, and survival appears to be worse in NF1-associated tumors than i...... hiện toàn bộ
The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery
Current Oncology Reports - Tập 19 - Trang 1-6 - 2017
Angela M. Stover, Ethan M. Basch
The American Society of Clinical Oncology (ASCO) palliative care recommendations have been updated into a full guideline. Symptom questionnaires—completed and reviewed with patients during care delivery—are poised to play a large role in this guideline because they provide a more comprehensive understanding of symptoms. This article provides an overview of the guideline and describes how symptom q...... hiện toàn bộ
Second Primary Tumors in Patients with Head and Neck Cancer
Current Oncology Reports - Tập 13 - Trang 132-137 - 2011
Antonio Vitor Martins Priante, Emanuel Celice Castilho, Luiz Paulo Kowalski
This is a review on second primary tumors in patients with head and neck cancer. These patients have a high risk of developing other cancers simultaneously or subsequently. The incidence of multiple primary tumors in this population can be as high as 27%. Recurrences are the most common cause of treatment failure within the first 2 years of follow-up. After the third year the diagnosis of a second...... hiện toàn bộ
Risk assessment models to estimate cancer probabilities
Current Oncology Reports - Tập 9 - Trang 503-508 - 2008
Constance M. Johnson, Derek Smolenski
Cancer risk has become a significant research topic due to an increase in statistical risk models built to predict cancer incidence or mortality. Over the past 3 years, 15 models on the development of different types of cancer, including breast, colorectal, prostate, gastric, lung, ovarian, pancreatic, testicular, and skin, have been published. Risk assessment models are dynamic; they need to be u...... hiện toàn bộ
Targeting KRAS in Colorectal Cancer
Current Oncology Reports - Tập 23 - Trang 1-10 - 2021
Chongkai Wang, Marwan Fakih
Mutations in kirsten rat sarcoma viral oncogene homolog (KRAS) are the most frequently observed genomic alterations in human cancers. No KRAS targeting therapy has been approved despite more than three decades of efforts. Encouraging progress has been made in targeting KRASG12C with KRASG12C specific covalent inhibitors in the past few years. Herein, we review the recent breakthroughs in KRAS targ...... hiện toàn bộ
Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin
Current Oncology Reports - Tập 3 - Trang 131-140 - 2001
Roy S. Herbst, Anh Tuyet Lee, Hai T. Tran, James L. Abbruzzese
Most solid-tumor malignancies remain incurable. Novel agents that target and counteract biologic mechanisms are now being developed. It is hoped that these drugs will allow for more effective, less toxic cancer treatments and long-term maintenance approaches. One important class of agents functions by an anti-angiogenic mechanism, targeting the blood vessel supply of the tumor and inhibiting tumor...... hiện toàn bộ
Gene Delivery in Neuro-Oncology
Current Oncology Reports - Tập 19 Số 11 - 2017
Karan Dixit, Priya Kumthekar
Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
Current Oncology Reports - Tập 24 - Trang 1337-1349 - 2022
Amparo Belltall, Guido Mazzinari, Oscar Diaz-Cambronero, Pilar Eroles, María Pilar Argente Navarro
Antagonists of mu-opioid receptor role in cancer progression remains to be elucidated. The objective of this review was to summarize the available evidence on antagonists of mu-opioid receptor effect on tumor progression and prognosis in different types of cancers and an evaluation of the available findings on their mechanism of action. We have found studies related to methylnaltrexone (MNTX) and ...... hiện toàn bộ
Chimeric Antigen Receptor–Engineered T Cell Therapy in Lymphoma
Current Oncology Reports - Tập 21 - Trang 1-7 - 2019
Paolo Strati, Sattva S. Neelapu
Chimeric antigen receptor (CAR) T cells are a form of adoptive therapy employing autologous T cells engineered with an artificial receptor, able to recognize tumor antigens through an HLA-independent mechanism. We will review data on safety and efficacy outcomes with CAR T cell therapy in lymphomas. Multicenter trials evaluating three CAR T cell products targeting CD19 have shown that they are hig...... hiện toàn bộ
Tổng số: 1,493   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10